For 2025, we expect sales erosion driven by biosimilar competition. Nplate® (romiplostim) sales decreased 13% year-over-year to $337 million in the fourth quarter. Excluding a fourth quarter 2023 U.S. government order of $62 million, Nplate sales grew 4% year-over-year in the fourth ...
Additional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS®) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif.,Dec. 8, 2023/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pip...
AMGN US0311621009 Pharmaceuticals Market Closed -Nasdaq 04:00:00 2025-05-20 pm EDT5-day change1st Jan Change 275.01USD-0.30% +0.09%+5.51% May. 16Weight-loss drug developers line up to tap lucrative market as competition heats upRE
Our teams moved quickly to engage retina specialists, and we're encouraged by the enthusiastic feedback from customers. Our teams are also ready for the upcoming U.S. launches of WEZLANA, a biosimilar to STELARA and BEKEMV, a biosimilar to Solaris, expected in the first and second quarters ...
Good afternoon and thanks for taking my question. Let's start with the immunology theme here. You guys are developing both STELARA and HUMIRA for 2023, 2024's biosimilars. And given you're going to be in both sides of the innovator of biosimilar world, I was wondering if you had a thou...
population that treat the many women who are trying to reduce their risk of fracture despite the effect of their osteoporosis, we feel really good about it. And yes, it could end up becoming something that helps us in terms of market presence in the face of biosimilar competition in th...